product name Beclomethasone dipropionate
Description: Beclomethasone dipropionate(also called BDP) is a topically active and anti-inflammatory corticosteroid used in treatment of asthma and rhinitis. In addition, Beclomethasone dipropionate has been reported to be previously developed as aqueous nasal formulations for the treatment of Allergic rhinitis. Moreover, Beclomethasone dipropionate has shown the availability in dry nasal aerosol formulations as chiorofluoro carbon metered-dose inhaler nasal sprays.
References: Clin Ther. 2012 Jun;34(6):1422-31; J Allergy Clin Immunol. 1999 Dec;104(6):1215-22.
521.04
Formula
C28H37ClO7
CAS No.
5534-09-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 104 mg/mL (199.6 mM)
Water: <1 mg/mL
Ethanol: 18 mg/mL (34.5 mM)
Solubility (In vivo)
Synonyms
Beclometasone dipropionate
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19422983
| In Vitro |
In vitro activity: Beclomethasone dipropionate (BDP) is an anti-inflammatory corticosteroid available for the treatment of asthma and allergic rhinitis (AR). BDP is previously developed as aqueous nasal formulations for the treatment of AR. BDP is also available in dry nasal aerosol formulations as chlorofluoro carbon (CFC) metered-dose inhaler nasal sprays, but CFC-containing formulations have been withdrawn from the market and currently are not available.BDP hydrofluoroalkane (HFA) inhalation aerosol currently is available for patient use and indicated for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.BDP HFA nasal aerosol, an intranasal aerosol formulation, has been developed recently for the treatment of AR. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Clin Ther. 2012 Jun;34(6):1422-31; J Allergy Clin Immunol. 1999 Dec;104(6):1215-22. |
